Rocket Pharmaceuticals In... (RCKT)
6.28
0.47 (8.09%)
At close: Apr 02, 2025, 3:59 PM
5.95
-5.32%
After-hours: Apr 02, 2025, 07:53 PM EDT
8.09% (1D)
| Bid | 5.88 |
| Market Cap | 669.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.73 |
| PE Ratio (ttm) | -2.3 |
| Forward PE | -4.51 |
| Analyst | Buy |
| Ask | 7.22 |
| Volume | 3,994,712 |
| Avg. Volume (20D) | 1,672,928 |
| Open | 5.72 |
| Previous Close | 5.81 |
| Day's Range | 5.71 - 6.31 |
| 52-Week Range | 5.70 - 26.98 |
| Beta | 1.02 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 18, 2015
Employees 299
Stock Exchange NASDAQ
Ticker Symbol RCKT
Website https://rocketpharma.com
Analyst Forecast
According to 10 analyst ratings, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 648.41% from the latest price.
Stock Forecasts3 months ago
-2.38%
Rocket Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
5 months ago
+8.27%
Rocket Pharmaceuticals shares are trading higher after Scotiabank initiated coverage on the stock with a Sector Outperform rating on the stock and announced a $50 price target.
